Results 141 to 150 of about 43,675 (258)

EZH2 in Acral Lentiginous Melanoma: Molecular, Epigenetic, and Therapeutic Perspectives. [PDF]

Oncol Res
de Oliveira DA, Nisimoto MYSM, Hunnicutt JMS, Sartori EM, Marques AF, Paschoal FM, Marti LC, Jasiulionis MG, Neto MS, Filho RSO.   +9 more
europepmc   +1 more source

Decoding the Heterogeneity of Diffuse Large B‐Cell Lymphomas: A Comprehensive Genetic, Transcriptomic, and Phenotypic Profiling of B‐Cell Lymphoma Cell Lines

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most prevalent form of non‐Hodgkin lymphoma, exhibiting significant molecular and clinical heterogeneity. Advances in classification integrating phenotypic, genetic, and transcriptomic features have improved diagnosis and prognosis.
Marina Pérez‐Aguilera, Lucía Pedrosa, Sagrario Gómez, Sara Salazar‐Ortego, Ismael Fernández‐Miranda, Rafael Muñoz‐Viana, Paloma Martín‐Acosta, Beatriz L. Martín‐Lunas, Rebeca Jimeno, Natalia Yanguas‐Casás, Beatriz Horcajo, Giovana Roncador, José A. Martínez‐Climent, Ana Ortega‐Molina, Margarita Sánchez‐Beato   +14 more
wiley   +1 more source

EZH2 inhibition via GSK-126 mitigates EndMT and atherosclerosis in diabetes: A translational epigenetic approach. [PDF]

Sci Adv
Aziz M, Sourris KC, Pinzon-Cortes JA, Block TJ, Dai A, Maxwell S, Okabe J, Calkin AC, Cooper ME, Jandeleit-Dahm KAM, Khan AW.   +10 more
europepmc   +1 more source

Circulating Tumor DNA and Immune Response Markers for Improved Treatment Outcome Prediction in Diffuse Large B‐Cell Lymphoma: A Scoping Review

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Early identification of refractory disease remains a significant unmet clinical need in patients with diffuse large B‐cell lymphoma (DLBCL). This scoping review was conducted to assess the current knowledge on the use of circulating tumor DNA (ctDNA), either alone or in combination with immune markers, as predictive tools for treatment outcome
Ailin McMahon, Elizabeth J. Ryan, Sarah Dillon, Ruth Clifford   +3 more
wiley   +1 more source

The role of <i>EZH2</i> dysregulation in the pathogenesis of B-cell lymphomas and its implications as a target therapy. [PDF]

Front Oncol
Candelaria M.
europepmc   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

MedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng, Zhipeng Shen, Yuanfang Wu, Xingze Huang, Zhongyuan Zhang, Jiangyu Liu, Qichun Wei, Wenhao Chen, Ye Chen, Liang Xu   +9 more
wiley   +1 more source

MEF2A nuclear translocation mediated by ROCK phosphorylation promotes EZH2 expression and peritoneal fibrosis. [PDF]

Ren Fail
Chen D, Sun Z, Xu Y, Wang Q.
europepmc   +1 more source

Metabolism in Tumor: Mechanisms and Therapeutic Perspectives

MedComm, Volume 7, Issue 9, September 2026.
Tumor metabolic reprogramming converges on three hubs—the SREBP1/2–FASN–SCD1 lipogenic axis, the HIF‐1α–GLUT1–LDHA glycolytic axis, and the LDLR–SCARB1–LXR cholesterol system—which integrate transcriptional, epigenetic (histone lactylation, m6A), and microenvironmental inputs to generate metabolic plasticity, immune evasion, and therapy resistance ...
Jia‐Chen Cheng, Yi‐Xuan Hu, Xiang‐Chun Huang, Shan Jiang, Jie‐Lin Wang, Yang Zhao, Shuo Chen   +6 more
wiley   +1 more source

EZH2 blockade reverses doxorubicin resistance by inducing metabolic vulnerability and enhancing DNA damage in breast cancer. [PDF]

Front Pharmacol
Wang X, Ding Y, Mai Y, Li R, Shao X, Chen W, Li Y, Liu L, Wang H, Liu K, Niu Y, Li J, Xu G, Zhao Y.   +13 more
europepmc   +1 more source

Prostate Cancer Development, Progression, and Therapy

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides an integrated overview of prostate cancer development, progression, and therapy, spanning historical milestones, molecular mechanisms, advanced research models, and emerging therapeutic strategies. It highlights recent advances in precision diagnosis, lineage plasticity, therapy resistance, and next‐generation treatments for ...
Xin Jin, Zicheng Xiao, Zexian Ding, Wei Li, Ruijiang Zeng, Yujun Shuai, Weimin Ci, Dan Xia, Xu Zhang, Haojie Huang   +9 more
wiley   +1 more source